Intermittent, three-times-weekly oral antibiotic therapy is recommended for the initial treatment of noncavitary nodular bronchiectatic (NB) Mycobacterium avium complex (MAC) lung disease. However, intermittent therapy is not recommended for patients who have been previously treated. We evaluated 53 patients with recurrent noncavitary NB MAC lung disease who underwent antibiotic treatment for ≥12 months with daily therapy (n = 26) or intermittent therapy (n = 27) between January 2008 and December 2015. Baseline characteristics were comparable between daily therapy and intermittent therapy groups. Sputum culture conversion rates did not differ between daily therapy (21/26, 81%) and intermittent therapy (22/27, 82%) groups. Compared to the etiologic organism at the time of previous treatment, recurrent MAC lung disease was caused by the same MAC species in 38 patients (72%) and by a different MAC species in 15 patients (28%). Genotype analysis in patients with sequenced paired isolates revealed that 86% (12/14) of cases with same species recurrence were due to reinfection with a new MAC genotype. In conclusion, most recurrent noncavitary NB MAC lung disease cases were caused by reinfection rather than relapse. Intermittent antibiotic therapy is a reasonable treatment strategy for recurrent noncavitary NB MAC lung disease.
|Journal||Antimicrobial agents and chemotherapy|
|Publication status||Published - 2018 Feb|
Bibliographical noteFunding Information:
We thank Soohyun Ahn, a statistician in Samsung Medical Center, for help with the statistical analysis. C.L.D. received grants from Insmed, Inc., not associated with the submitted work. Otherwise, we have no conflicts of interest to declare. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (NRF-2015R1A2A1A01003959) and by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (HI15C2778). The sponsor had no role in the design of the study, collection, and analysis of the data, or preparation of the manuscript.
for her help in statistical analysis. Dr. Charles L. Daley has received grants from Insmed Inc.
Copyright © 2018 American Society for Microbiology. All Rights Reserved.
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Infectious Diseases